1. Home
  2. CHRS vs SPKL Comparison

CHRS vs SPKL Comparison

Compare CHRS & SPKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • SPKL
  • Stock Information
  • Founded
  • CHRS 2010
  • SPKL 2021
  • Country
  • CHRS United States
  • SPKL United States
  • Employees
  • CHRS N/A
  • SPKL N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • SPKL
  • Sector
  • CHRS Health Care
  • SPKL
  • Exchange
  • CHRS Nasdaq
  • SPKL Nasdaq
  • Market Cap
  • CHRS 191.3M
  • SPKL 174.6M
  • IPO Year
  • CHRS 2014
  • SPKL 2023
  • Fundamental
  • Price
  • CHRS $1.46
  • SPKL $10.68
  • Analyst Decision
  • CHRS Strong Buy
  • SPKL
  • Analyst Count
  • CHRS 4
  • SPKL 0
  • Target Price
  • CHRS $5.38
  • SPKL N/A
  • AVG Volume (30 Days)
  • CHRS 2.3M
  • SPKL 44.7K
  • Earning Date
  • CHRS 11-06-2024
  • SPKL 01-01-0001
  • Dividend Yield
  • CHRS N/A
  • SPKL N/A
  • EPS Growth
  • CHRS N/A
  • SPKL N/A
  • EPS
  • CHRS N/A
  • SPKL 0.19
  • Revenue
  • CHRS $304,340,000.00
  • SPKL N/A
  • Revenue This Year
  • CHRS $2.47
  • SPKL N/A
  • Revenue Next Year
  • CHRS N/A
  • SPKL N/A
  • P/E Ratio
  • CHRS N/A
  • SPKL $57.50
  • Revenue Growth
  • CHRS 44.19
  • SPKL N/A
  • 52 Week Low
  • CHRS $0.66
  • SPKL $10.18
  • 52 Week High
  • CHRS $2.97
  • SPKL $11.95
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 49.74
  • SPKL 64.21
  • Support Level
  • CHRS $1.44
  • SPKL $10.63
  • Resistance Level
  • CHRS $1.60
  • SPKL $10.68
  • Average True Range (ATR)
  • CHRS 0.12
  • SPKL 0.02
  • MACD
  • CHRS -0.02
  • SPKL 0.00
  • Stochastic Oscillator
  • CHRS 25.00
  • SPKL 98.86

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About SPKL Spark I Acquisition Corp.

Spark I Acquisition Corp is a Blank check company.

Share on Social Networks: